About Us
Fresenius Kabi at a glance
Our product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. In the field of biosimilars, we focus on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.
Fresenius Kabi employs around 43,000 people worldwide.
We are committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.
In 2023 we reported sales of more than €8.0 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group.
